Expertise in
1
conditions

Dr. Ronnie Neuberg

Hematology | Oncology
Office
7 Richland Medical Park Dr Ste 7215, 
Columbia, SC 
Expertise in
1
conditions
Office
7 Richland Medical Park Dr Ste 7215, 
Columbia, SC 

Overview

Ronnie Neuberg is a Hematologist and an Oncologist practicing medicine in Columbia, South Carolina.

Dr. Neuberg is highly rated in 1 condition, according to our data. His clinical expertise encompasses Osteoporosis, Relapsing Multiple Sclerosis (RMS), Infantile Neutropenia, and Pineoblastoma.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 26 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
7 Richland Medical Park Dr Ste 7215, Columbia, SC 29203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Other, Procedure
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Other, Drug
Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib
Study Phase: Phase 3
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Completed
Publish Date: May 28, 2026
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Other
Key Adverse Events After Childhood Cancer
Key Adverse Events After Childhood Cancer
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Other
View 9 Less Clinical Trials

1 Total Publications

Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.
Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.
Journal: Pediatric blood & cancer
Published: February 26, 2015
Similar Doctors
Expertise in
70
conditions
Dr. Mohamed M. Geneidy
Hematology | Oncology
Expertise in
70
conditions
Dr. Mohamed M. Geneidy
Hematology | Oncology
Referral may be required

MUSC Health Kershaw Medical Center

1315 Roberts Street, 
Camden, SC 
 (35.1 miles away)
803-432-4311
Experience:
31+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Mohamed El Geneidy, MD, specializes in Hematology/Oncology and is located in Camden, SC. Dr. Geneidy is highly rated in 70 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Gastrostomy. Dr. Geneidy is currently accepting new patients.

Expertise in
85
conditions
Dr. Steven Madden
Hematology | Oncology
Expertise in
85
conditions
Dr. Steven Madden
Hematology | Oncology
Referral may be required

Lexington Medical Cancer Center Hematology/Oncology

222 E Medical Ln Ste 400, 
West Columbia, SC 
 (2.1 miles away)
803-794-7511
Languages Spoken:
English
See accepted insurances

Steven Madden is a Hematologist and an Oncologist practicing medicine in West Columbia, South Carolina. Dr. Madden is highly rated in 85 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Bone Marrow Aspiration, and Endoscopy.

Expertise in
75
conditions
Dr. Scott R. Sommers
Hematology | Oncology
Expertise in
75
conditions
Dr. Scott R. Sommers
Hematology | Oncology
Referral may be required

MUSC Health Kershaw Medical Center

1315 Roberts Street, 
Camden, SC 
 (35.1 miles away)
803-432-4311
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Sommers, MD, specializes in Hematology/Oncology and is located in Camden, SC. Dr. Sommers is highly rated in 75 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, Breast Cancer, and Bone Marrow Aspiration. Dr. Sommers is currently accepting new patients.

Frequently Asked Questions about Dr. Ronnie Neuberg

How do I make an appointment with Dr. Ronnie Neuberg?

You can book an appointment with Dr. Ronnie Neuberg by calling their office at 803-296-2273. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ronnie Neuberg a top-rated expert for Osteoporosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ronnie Neuberg is classified as an Advanced expert for Osteoporosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ronnie Neuberg specialize in?

While Dr. Ronnie Neuberg is a Hematology, they have specific expertise in Osteoporosis, Relapsing Multiple Sclerosis (RMS), and Infantile Neutropenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ronnie Neuberg participate in research or clinical trials?

Yes. Dr. Ronnie Neuberg has published 1 articles and abstracts on conditions like Osteoporosis. You can view a list of Dr. Ronnie Neuberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ronnie Neuberg accept my insurance?

Dr. Ronnie Neuberg accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 803-296-2273 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Neuberg's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile